Find comprehensive information on Small Lymphocytic Lymphoma (SLL) diagnosis, including clinical documentation requirements, ICD-10-CM codes (C83.10), medical coding guidelines, and healthcare best practices. Learn about SLL staging, prognosis, and treatment options. This resource offers valuable insights for healthcare professionals, medical coders, and patients seeking information on SLL management and documentation.
Also known as
Nodal marginal zone B-cell lymphoma
Small lymphocytic lymphoma involving lymph nodes.
Splenic marginal zone lymphoma
Small lymphocytic lymphoma primarily affecting the spleen.
Extranodal marginal zone B-cell lymphoma
Small lymphocytic lymphoma found outside lymph nodes or spleen.
Chronic lymphocytic leukemia/small lymphocytic lymphoma
Small lymphocytic lymphoma with or without involvement of the blood.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the diagnosis Small Lymphocytic Lymphoma?
When to use each related code
| Description |
|---|
| Small Lymphocytic Lymphoma |
| Chronic Lymphocytic Leukemia |
| Mantle Cell Lymphoma |
Q: What are the key differentiating factors in the differential diagnosis of Small Lymphocytic Lymphoma (SLL) versus Chronic Lymphocytic Leukemia (CLL), and how do these differences impact initial treatment strategies?
A: Small Lymphocytic Lymphoma (SLL) and Chronic Lymphocytic Leukemia (CLL) are essentially the same disease from a cellular and molecular standpoint, distinguished primarily by the location of the malignant lymphocytes. SLL is defined by the accumulation of these cells in lymph nodes and other lymphoid tissues, while CLL is characterized by a predominant involvement of the bone marrow and peripheral blood with a lymphocyte count greater than or equal to 5 x 10^9/L. While the initial presentation and staging may differ, treatment strategies for both SLL and CLL are largely similar and are guided by factors like patient age, disease stage, presence of specific genetic mutations (e.g., del(17p), TP53 mutation), and overall health status. However, the threshold for initiating treatment may be lower in CLL due to the higher risk of complications like cytopenias. Explore how risk stratification algorithms like the iwCLL score can help guide treatment decisions in both SLL and CLL.
Q: What are the most recent advancements in targeted therapies for managing relapsed/refractory Small Lymphocytic Lymphoma (SLL), and how do these therapies compare to traditional chemoimmunotherapy approaches in terms of efficacy and toxicity profiles?
A: Recent years have seen significant advancements in the treatment landscape for relapsed/refractory Small Lymphocytic Lymphoma (SLL) with the introduction of novel targeted agents like Bruton tyrosine kinase (BTK) inhibitors (e.g., ibrutinib, acalabrutinib), B-cell lymphoma 2 (BCL2) inhibitors (e.g., venetoclax), and PI3K inhibitors (e.g., idelalisib). These agents offer improved efficacy and often more favorable toxicity profiles compared to traditional chemoimmunotherapy regimens, particularly in patients with high-risk features like del(17p). While targeted therapies tend to be better tolerated, they are associated with specific side effects that require careful monitoring. For instance, BTK inhibitors can increase the risk of atrial fibrillation and bleeding, while BCL2 inhibitors can cause tumor lysis syndrome. Consider implementing a patient-specific risk assessment before initiating targeted therapy. Learn more about the latest clinical trial data comparing these novel agents with traditional approaches in SLL.
Subjective: Patient presents with complaints of fatigue, lymphadenopathy, and unintentional weight loss. Onset of symptoms reported as gradual over the past several months. Patient denies fever, night sweats, or bone pain. Review of systems is otherwise unremarkable. Past medical history includes hypertension, well-controlled with medication. Family history is notable for a maternal aunt with chronic lymphocytic leukemia. Social history is negative for tobacco use or excessive alcohol consumption. Objective: Physical examination reveals palpable, non-tender cervical and axillary lymphadenopathy. Spleen is palpable 2 cm below the left costal margin. No hepatomegaly noted. Cardiovascular, pulmonary, and abdominal examinations are otherwise unremarkable. Complete blood count demonstrates lymphocytosis with a white blood cell count of 25,000 cells per microliter, with 80% small, mature lymphocytes. Flow cytometry performed on peripheral blood confirms a clonal B-cell population expressing CD19, CD20, CD5, and CD23, consistent with small lymphocytic lymphoma. Bone marrow biopsy reveals infiltration by small lymphocytes. Imaging studies, including a CT scan of the chest, abdomen, and pelvis, show generalized lymphadenopathy and splenomegaly. No evidence of bone lesions or other extranodal involvement identified. Assessment: Diagnosis of small lymphocytic lymphoma (SLL), B-cell type, Rai stage III, is established based on clinical presentation, peripheral blood flow cytometry, bone marrow biopsy findings, and imaging studies. Differential diagnosis included other types of non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and other lymphoproliferative disorders. Given the Rai stage and presence of symptoms, treatment is indicated. Plan: Discussed treatment options with the patient, including watch and wait approach versus initiation of chemotherapy. Risks and benefits of each approach were reviewed. Considering the patient's symptoms and disease stage, the patient elected to proceed with chemoimmunotherapy. Treatment plan will consist of rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP). Patient education provided regarding potential side effects of treatment, including neutropenia, thrombocytopenia, and infection risk. Follow-up appointments scheduled for monitoring of treatment response and management of potential complications. Referral to oncology and hematology specialists made for ongoing care and support. Patient provided with information regarding support groups and resources for patients with lymphoma. ICD-10 code C83.1 (Small lymphocytic lymphoma) assigned.